BioCraft Publishes Cultivated Pet Food's First Public Safety Dossier to Set the Category's Trust Bar

BioCraft Pet Nutrition released the first complete, publicly available safety record for a cell-cultured pet food ingredient on July 17, then paired it with a proposed disclosure standard the rest of the category would have to meet. In a market where regulators clear factories but not the ingredients that come out of them, the first company to open its data gets to define what "safe enough" looks like.

BioCraft Put Its Mouse-Cell Ingredient Through Cancer, Toxicity, and Viral Testing, Then Posted the Whole File Publicly

BioCraft, the Austrian-American company formerly known as Because Animals and led by co-founder and chief executive Shannon Falconer, published a full safety dossier for PE25, the mouse embryonic stem cell line behind its cultivated-meat ingredient. The filing went up on the preprint server bioRxiv, which means it is public but not yet peer-reviewed.

The document walks through the tests a skeptical buyer would ask for. Cell-line identity and tumorigenicity work, including a soft agar assay, a p53 DNA-damage response check, and CD44 and BMI1 marker screening, turned up no cancer-like traits. Standard genotoxicity assays came back non-genotoxic. Heavy metals, biogenic amines, and solvent residues sat below regulatory limits, and the company reported viral safety and growth-media compliance. The finished ingredient, BioCraft notes, contains no living cells, and its taurine, lysine, methionine, and tryptophan levels track a conventional chicken slurry.

Alongside the data, BioCraft introduced what it calls the BioCraft Pet Nutrition Standard, a proposed set of minimum disclosure requirements for the field that would account for the different cell-line origins, growth media, and processing methods competitors use. The company registered its ingredients with Austrian authorities in early 2025, has a manufacturing partnership with Prefera Petfood, and has said its products will land first in European markets.

In a Category With No Ingredient-Level Safety Review, the First Full Dossier Becomes the Benchmark Everyone Else Answers To

The move only makes sense against the regulatory vacuum it steps into. In the EU and UK, registration covers the production facility, not the ingredient itself, and no independent body reviews cultivated ingredients against a shared safety bar. In the US, the FDA and AAFCO pathway for these ingredients is still unformed. There is, in other words, no external benchmark for a cultivated pet food ingredient, which is exactly why publishing one matters.

Three implications follow for operators watching the novel-protein space.

1. The first complete disclosure becomes the reference point. Rivals working other routes, from Bond Pet Foods' fermentation-made proteins to Wild Earth's fungal ingredients to the cultivated bets inside CULT Food Science's portfolio, now either match BioCraft's transparency or look opaque by comparison. Disclosure is cheap for a first mover with clean data and expensive for anyone whose data is messier, which makes it a competitive weapon, not just a courtesy.
2. A company-authored standard is written by an interested party. A framework BioCraft designed will, unsurprisingly, reward the things BioCraft does well. But filling a vacuum still confers agenda-setting power, and regulators drafting rules later often borrow the scaffolding that already exists.
3. For formulators and brands weighing a cultivated ingredient, a public dossier lowers the cost of diligence and de-risks a first conversation. The caveats are real: a preprint is not peer review, and a facility registration is not an ingredient approval, so the regulatory question stays open even as the data question gets easier.

The pattern is familiar. This is the same transparency reflex driving clean-label reformulation across kibble, applied to the most trust-sensitive corner of the ingredient market. "Lab-grown" still reads as a liability to plenty of pet owners, and a stack of published safety data is as much a consumer-trust play as a scientific one.

Whether Rivals Match the Disclosure Will Decide If Transparency Becomes Cultivated Pet Food's Cost of Entry

The signal to track is whether competitors answer with dossiers of their own. Broad adoption would validate BioCraft's standard and turn disclosure into table stakes; silence would leave BioCraft owning the category's trust narrative by default. Watch, too, for any movement from AAFCO, the FDA's Center for Veterinary Medicine, or EFSA toward ingredient-level review, and for whether BioCraft's data feeds a formal regulatory submission rather than sitting on a preprint server.

On the commercial side, the tells are named manufacturing partners like Prefera moving from agreement to shelf, any concrete step toward the US market, and whether earlier price-parity claims survive contact with real production volume. And the preprint itself bears watching: peer review will either harden the safety story or complicate it, and a claim is not yet a verdict.

For operators, the decision this informs is narrow but real. A brand scouting a differentiated protein now has a data package to run diligence against, and an investor sizing up the cultivated field has a first read on which players intend to compete on trust rather than just cost.

Source: BioCraft Pet Nutrition, "BioCraft Pet Nutrition Sets the Transparency Standard for Animal Cell-Cultured Pet Food, with the Category's First Public Safety Dossier," and the company's safety dossier posted to bioRxiv, July 17, 2026.